share_log

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics

Benzinga ·  Nov 20, 2024 22:00

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE) in the last three months.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings02620
Last 30D00000
1M Ago02300
2M Ago00320
3M Ago00000

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.2, a high estimate of $26.00, and a low estimate of $4.00. Highlighting a 33.7% decrease, the current average has fallen from the previous average price target of $18.40.

bigjpg

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Sage Therapeutics...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment